Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712196 | 0.79 | GSK3B (0.48) | GSK3BRAB9AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL1711929 | 0.79 | NPC1 (0.47) | RAB9ACA1CA2ALDH1A1MAPT | |
| SCHEMBL1712729 | 0.78 | TDP1 (0.47) | GSK3BRAB9AALDH1A1MAPTTDP1 | |
| SCHEMBL6230747 | 0.78 | SNCA (0.54) | GSK3BCA1CA2ALDH1A1MAPT | |
| SCHEMBL1968295 | 0.76 | HDAC3 (0.53) | GSK3BRAB9AALDH1A1MAPTKMT2A | |
| 4-Cyanophenol SCHEMBL8772622 | 0.75 | CA12 (0.59) | GSK3BCA2ALDH1A1P4HB | |
| SCHEMBL320736 | 0.75 | GSK3B (0.59) | GSK3BRAB9ACA1CA2ALDH1A1 | |
| SCHEMBL27269021 | 0.75 | L3MBTL1 (0.54) | ALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL10562829 | 0.73 | ALDH1A1 (0.55) | RAB9AALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL28083744 | 0.72 | GSK3B (0.66) | GSK3BRAB9ACA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344460-B1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8383608-B2 | Imidazolidine compounds as androgen receptor modulators | DART THERAPEUTICS LLC | 2013-02-26 | — | — | US | disclosed |
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2344460-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Galapagos N.V. (BE) | 2011-07-20 | — | — | EP | disclosed |
| US-7968581-B2 | Imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010029119-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | GALAPAGOS NV (BE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | GSK3B 2141/4885RAB9A 1006/4885CA1 4697/4885 |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | GSK3B 2317/4885RAB9A 1328/4885CA1 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.